ESMO Congress 2022

Results from the RADICALS-HD and PRESTO trials show encouraging metastasis-free and biochemical progression-free survival benefits with androgen deprivation therapy, but they are not practice-changing yet

Results from the COSMIC-313 trial show that adding cabozantinib to nivolumab plus ipilimumab prolongs progression-free survival, but also increases toxicity 

Results from the CodeBreaK 200 trial represent an improvement for a difficult-to-treat patient population 

Findings show overall survival benefits with front-line atezolizumab versus single-agent chemotherapy, but questions remain regarding who might benefit 

Study data report promising responses and safety profiles in patients with heavily pre-treated malignancies

In the OCLURANDOM trial, progression-free survival was longer in patients receiving lutetium-octreotate versus sunitinib

The optimal chemotherapy regimen in this setting is not well-defined 

Immunotherapy typically requires intravenous administration, but this may not be the optimal or preferred route for all patients 

Results of a small phase II trial may open up a new option for some patients with leukoplakia, but toxicity of immunotherapy is high and questions remain about its utility in clinical practice 

Encouraging clinical activity was reported for fruquintinib and the combination therapy of trastuzumab plus tucatinib in heavily pre-treated patients with manageable safety profiles